Form 8-K - Current report:
SEC Accession No. 0001104659-24-119760
Filing Date
2024-11-15
Accepted
2024-11-15 16:57:18
Documents
15
Period of Report
2024-11-15
Items
Item 2.05: Cost Associated with Exit or Disposal Activities
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2428238d1_8k.htm   iXBRL 8-K 26465
2 EXHIBIT 99.1 tm2428238d1_ex99-1.htm EX-99.1 11633
6 GRAPHIC image_002.jpg GRAPHIC 6107
  Complete submission text file 0001104659-24-119760.txt   224854

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE eyen-20241115_lab.xml EX-101.LAB 34240
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE eyen-20241115_pre.xml EX-101.PRE 22359
5 XBRL TAXONOMY EXTENSION SCHEMA eyen-20241115.xsd EX-101.SCH 3015
17 EXTRACTED XBRL INSTANCE DOCUMENT tm2428238d1_8k_htm.xml XML 3676
Mailing Address 295 MADISON AVENUE, SUITE 2400 NEW YORK NY 10017
Business Address 295 MADISON AVENUE, SUITE 2400 NEW YORK NY 10017 813-766-9539
EYENOVIA, INC. (Filer) CIK: 0001682639 (see all company filings)

EIN.: 471178401 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38365 | Film No.: 241468676
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)